TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01814748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin 25 mg capsule administered orally once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to omarigliptin
Description: Matching placebo to omarigliptin 25 mg capsule administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
Study: NCT01591382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intravenous (IV) ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who received ketamine-matching placebo were given saline infusions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone PCA
Description: Intravenous hydromorphone PCA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone PCA
Description: Intravenous hydromorphone PCA
Study: NCT03393195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted Eating plan
Description: Research team will prescribe an eating plan for the participant to follow for the 12 week study. The eating plan will consist of eating during a specified 8 hour window and fasting for the remaining 16 hours of the day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consistent Meal timing plan
Description: Research team will prescribe an eating plan for the participant to follow for the 12 week study.The eating plan will consist of eating three structured meals each day during three specified meal windows.
Study: NCT00939874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
Study: NCT00330174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: 2 333mg tablets three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acamprosate
Description: 2 333mg tablets three times daily
Study: NCT02231177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1744 CL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL/Tiotropium FDC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Study: NCT01954355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: 400, 600 and 800 mg OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 (days 1, 8, 15)
Study: NCT00954148

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT
Description: 5 visits with PET/CT as only testing

Intervention type: PROCEDURE
Group type: OTHER
Intervention: NCCN recommendations for solid tumor post treatment
Description: 12-14 visits with exams, blood tests, CTs and PET/CT
Study: NCT01059630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: IV infusion.
Study: NCT02111577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/PCa
Description: DCVAC/PCa concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). DCVAC/PCa was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of DCVAC/PCa was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). Placebo was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of placebo was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
Study: NCT04321174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: The intervention is a 14-day course of LPV/r 400/100 mg orally twice daily, or equivalent weight-based dosing, to be initiated as soon as possible (within 1-7 days) after the last exposure.
Study: NCT01059630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: IV infusion.
Study: NCT03532802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate
Description: 1. week: uptitration with 50 mg capsules per day, until maximum dosage of 150 mg´s/day.~2. week: steady state treatment with the maximum tolerated dose of the 1.week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 1. week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~2. week: steady state treatment with the maximum tolerated dose of the 1. week
Study: NCT02403180

Intervention type: DEVICE
Group type: OTHER
Intervention: DACP MF
Description: Nelfilcon A multifocal contact lenses
Study: NCT02720198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
Study: NCT02403180

Intervention type: DEVICE
Group type: OTHER
Intervention: PROCLEAR 1D MF
Description: Omafilcon A multifocal contact lenses
Study: NCT01048333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Formoterol Turbuhaler 9 μg and Placebo Diskus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Formoterol Turbuhaler 9 μg and Placebo Diskus
Study: NCT04334226

Intervention type: OTHER
Intervention: Interview
Description: Interviews will explore the patient's and caregiver's experiences and perceptions of ostomy surgery prior to the Bootcamp and after the Bootcamp from a physical, psychological, social, and spiritual perspective
Study: NCT03375281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: thermal ablation using radiofrequency for HCC
Study: NCT03610295

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPI group
Description: The patients underwent cataract extraction, posterior capsulotomy, anterior vitrectomy combined with prophylactic peripheral iridectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract extraction
Description: The patients underwent cataract extraction, posterior capsulotomy combined with anterior vitrectomy and leave the iris intact.
Study: NCT01896869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg administered IV (10mg/kg if treatment started prior to protocol v 6.3)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: 5x10\^8 cells administered in 6 intradermal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
Study: NCT03758963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: R:GEN Selective Retina Therapy
Description: Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues. SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE. Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered. Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: R:GEN Selective Retina Therapy
Description: Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues. SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE. Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered. Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.
Study: NCT02054806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT01919203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
Study: NCT02260453

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative coronary angiography
Description: If coronary disease is detected percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) is applied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard cardiac workup
Description: EKG, transthoracic cardiac echocardiogram
Study: NCT01876290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone and Ondansetron
Description: Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03687333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALGLUCOSIDASE ALFA (MYOZYME)
Description: Pharmaceutical form: cake or powder for injection~Route of administration: intravenous infusion
Study: NCT04299893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
Study: NCT04266327

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-printing Template-assisted CT-guided I-125 Seed Implantation
Description: (1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seed implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume;Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc.Regular follow-up was conducted after treatment.
Study: NCT02620176

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation
Description: Trans-auricular vagal nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation
Description: Trans-auricular vagal nerve stimulation
Study: NCT01287130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
Study: NCT03888664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma interferon
Description: 1st two weeks: gIFN 100 ugr/three times a week from the 3rd week: gIFN 200 ugr/ three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
Study: NCT01367028

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab, Docetaxel
Description: 6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab, Docetaxel, Bevacizumab
Description: 6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion Bevacizumab 15 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab+Docetaxel+NPLD
Description: 6 cycles - Day1 (Day22=Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min IV infusion NPLD 50 mg/m2 by 60 min i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab+Docetaxel+NPLD+Bevacizumab
Description: 6 cycles - Day1 (Day22= Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min i.v. infusion NPLD: 50 mg/m2 by 60 min i.v. infusion; Bevacizumab 15 mg/kg
Study: NCT01100554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep endoscopy
Description: Conscious sedation will be done under intravenous propofol infusion. The sedative level would be monitored and adjusted accord to the Bispectral Index monitor. After the adequate sedative level is achieved, a bronchoscopy (Olympus, BF) was inserted from the right nostril. The velopharynx, oropharynx, larynx, and hypopharynx obstructions were evaluated.
Study: NCT03521726

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin
Description: Twenty patients receive Intraluminal Amoxicillin eradication for H. pylori.

Intervention type: DRUG
Group type: OTHER
Intervention: Rabeprazole, Amoxicillin
Description: Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole, Amoxicillin) for 14 days.
Study: NCT00834106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.
Study: NCT03659448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGM-101
Description: A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.
Study: NCT00480701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]-IBVM
Description: Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.
Study: NCT04679181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedecine
Description: telemedical consultation
Study: NCT03022201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9701
Description: Following 2-week screening period, study participants in this group will be given a standard dose of DA-9701 (30 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidone
Description: Following 2-week screening period, study participants in this group will be given a standard dose of domperidone (10 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo domperidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo DA-9701
Study: NCT00621543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]
Description: When a subject has chosen a method of intra-uterine contraception and has agreed to participate in the study, she will have the intra-uterine device of her choice inserted according to the Food and Druga Administration (FDA) instructions.
Study: NCT01063101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fucoidan (extract of Laminaria japonica)
Description: Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose filled capsule - oral administration - 5 different dose levels - BID
Study: NCT02807636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL\*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL\*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
Study: NCT03448731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 50Mg Tablet
Description: Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1
Study: NCT04050410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine
Description: active drug given as 1 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill given as 1 dose
Study: NCT02609607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Description: Rectal suppository

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rectal suppository
Study: NCT06681961

Intervention type: OTHER
Group type: OTHER
Intervention: squatting with hip adduction (SQU-HA) group
Description: The intervention comprised three sets of 15 repetitions with resting 5-min between sets, followed by IT band stretching for five repetitions. Each participant performed the respective exercise 5 days a week, with 2 days of rest, for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: squatting with hip adduction (SQU-HA) group
Description: The intervention comprised three sets of 15 repetitions with resting 5-min between sets, followed by IT band stretching for five repetitions. Each participant performed the respective exercise 5 days a week, with 2 days of rest, for 8 weeks.
Study: NCT06685341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139
Description: YZJ-1139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139
Description: YZJ-1139

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Oral tablet